Viiv Healthcare

This study tests if a monthly or every-other-month injection can control HIV in people who still have detectable virus despite taking daily oral medication. About 332 participants will be randomly assigned to either the injectable treatment or continue standard oral therapy. The …

This study tests a new oral drug, VH4524184, taken with two standard HIV medicines (emtricitabine and tenofovir alafenamide) in 150 adults with HIV-1 who have never received treatment. The goal is to see if the new combination can suppress the virus as well as a current standard …

This study tests a new long-acting injectable drug called VH4524184 in healthy adults to see if it is safe and well-tolerated. The goal is to find a dose that could be used as a future HIV treatment, given as a shot instead of daily pills. About 268 healthy volunteers aged 18 to …

This study is checking the long-term safety and effectiveness of a long-acting injectable drug (CAB LA) for preventing HIV. About 3,500 people who were already in earlier HIV prevention studies will continue getting the shots and be monitored for new HIV infections and side effec…

This early-stage study tests a new long-acting injectable drug, VH4011499, for safety and how the body processes it. About 168 healthy adults without HIV will receive one or more doses. The goal is to see if the drug is safe and stays in the body long enough to potentially preven…

This early-stage study is testing a long-acting HIV drug called cabotegravir in 214 healthy adults. The goal is to see how the drug moves through the body and if it is safe when given as a shot. Participants do not have HIV and will not receive any direct treatment benefit, but t…